Catalog No.
DVV00354
Expression system
Mammalian Cells
Species reactivity
SARS-CoV-2
Host species
Human
Isotype
IgG1
Clonality
Monoclonal
Target
Receptor-Binding Domain, RBD, Spike glycoprotein, S glycoprotein, E2, Peplomer protein, Spike protein S1, S
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P0DTC2
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Clone ID
BA7535
Structure and dynamics of Alpha B.1.1.7 SARS-CoV-2 S-protein in complex with Fab of neutralizing antibody REGN10987., PMID:40043614
Structural basis for receptor-binding domain mobility of the spike in SARS-CoV-2 BA.2.86 and JN.1., PMID:39375326
COVID-19 Vaccination in Liver Cirrhosis: Safety and Immune and Clinical Responses., PMID:39360169
A single-dose intranasal live-attenuated codon deoptimized vaccine provides broad protection against SARS-CoV-2 and its variants., PMID:39187479
Evaluation of SARS-CoV-2-Specific IgY Antibodies: Production, Reactivity, and Neutralizing Capability against Virus Variants., PMID:39063218
Impact of shift work and other work-related factors on anti-SARS-CoV-2 spike-protein serum concentrations in healthcare workers after primary mRNA vaccination - a retrospective cohort study., PMID:38639178
Efficient Expression in Leishmania tarentolae (LEXSY) of the Receptor-Binding Domain of the SARS-CoV-2 S-Protein and the Acetylcholine-Binding Protein from Lymnaea stagnalis., PMID:38474455
Predicting virus Fitness: Towards a structure-based computational model., PMID:37931730
Impact of BA.1, BA.2, and BA.4/BA.5 Omicron mutations on therapeutic monoclonal antibodies., PMID:37871435
Mapping SARS-CoV-2 antigenic relationships and serological responses., PMID:37797027
SARS-CoV-2 spike-protein targeted serology test results and their association with subsequent COVID-19-related outcomes., PMID:37559735
Immunogenicity, safety and reactogenicity of heterologous (third dose) booster vaccination with a full or fractional dose of two different COVID-19 vaccines: A phase 4, single-blind, randomized controlled trial in adults., PMID:37438960
Spike-protein proteolytic antibodies in COVID-19 convalescent plasma contribute to SARS-CoV-2 neutralization., PMID:37354908
Changes within the P681 residue of spike dictate cell fusion and syncytia formation of Delta and Omicron variants of SARS-CoV-2 with no effects on neutralization or infectivity., PMID:37292300
Cellular and humoral responses after second and third SARS-CoV-2 vaccinations in patients with autoimmune diseases treated with rituximab: specific T cell immunity remains longer and plays a protective role against SARS-CoV-2 reinfections., PMID:37180097
Long-Term Exposure to Air Pollution and COVID-19 Vaccine Antibody Response in a General Population Cohort (COVICAT Study, Catalonia)., PMID:37017430
Oral Immunization with Escherichia coli Nissle 1917 Expressing SARS-CoV-2 Spike Protein Induces Mucosal and Systemic Antibody Responses in Mice., PMID:36979504
Three doses of BNT162b2 COVID-19 mRNA vaccine establish long-lasting CD8+ T cell immunity in CLL and MDS patients., PMID:36703960
Tixagevimab/Cilgavimab in SARS-CoV-2 Prophylaxis and Therapy: A Comprehensive Review of Clinical Experience., PMID:36680160
Mechanistic model for booster doses effectiveness in healthy, cancer, and immunosuppressed patients infected with SARS-CoV-2., PMID:36623200
Dynamics of Humoral and Cellular Responses in Renal Transplant Recipients Receiving 3 Doses of SARS-CoV-2 mRNA Vaccine., PMID:36584381
International Practices on COVID-19 Vaccine Mandates for Transplant Candidates., PMID:36514724
BRAF inhibitor treatment of classical hairy cell leukemia allows successful vaccination against SARS-CoV-2., PMID:36494600
Differentially induced immunity in buccal and nasal mucosae after vaccination for SARS-CoV-2: Prospects for mass scale immunity-screening in large populations., PMID:36466833
Antibody tests for identification of current and past infection with SARS-CoV-2., PMID:36394900
Stability and expression of SARS-CoV-2 spike-protein mutations., PMID:36302994
Development of SARS-CoV-2 mRNA vaccines encoding spike N-terminal and receptor binding domains., PMID:36238717
Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination., PMID:36104115
DNA aptamers inhibit SARS-CoV-2 spike-protein binding to hACE2 by an RBD- independent or dependent approach., PMID:35910791
Antibody Response to SARS-CoV-2 Vaccines in People with Severe Obesity., PMID:35802279
SARS-COV-2 a trigger of myelin oligodendrocyte glycoprotein-associated disorder., PMID:35713508
COVID-19 vaccine associated transverse myelitis-Evusheld as an option when vaccination is not recommended due to severe adverse events., PMID:35511579
Development of antibody resistance in emerging mutant strains of SARS CoV-2: Impediment for COVID-19 vaccines., PMID:35416390
Humoral immunity in dually vaccinated SARS-CoV-2-naïve individuals and in booster-vaccinated COVID-19-convalescent subjects., PMID:35403960
ACE2 Serum Levels as Predictor of Infectability and Outcome in COVID-19., PMID:35401548
[Not Available]., PMID:35369108
Persistence of Naturally Acquired and Functional SARS-CoV-2 Antibodies in Blood Donors One Year after Infection., PMID:35337044
Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2., PMID:35052849
Kinetics and persistence of anti-SARS-CoV-2 neutralisation and antibodies after BNT162b2 vaccination in a Swiss cohort., PMID:34965032
B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients., PMID:34667083
SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients., PMID:34509643
Inhibition of SARS-CoV-2 pseudovirus invasion by ACE2 protecting and Spike neutralizing peptides: An alternative approach to COVID19 prevention and therapy., PMID:34345219
Comparison of the SARS-CoV-2 spike protein ELISA and the Abbott Architect SARS-CoV-2 IgG nucleocapsid protein assays for detection of antibodies., PMID:34324576
Emerging SARS-CoV-2 variant B.1.1.7 reduces neutralisation activity of antibodies against wild-type SARS-CoV-2., PMID:34298379
Exploratory analysis to identify the best antigen and the best immune biomarkers to study SARS-CoV-2 infection., PMID:34174875
Real-time, selective, and low-cost detection of trace level SARS-CoV-2 spike-protein for cold-chain food quarantine., PMID:34075052
Virological Characterization of Critically Ill Patients With COVID-19 in the United Kingdom: Interactions of Viral Load, Antibody Status, and B.1.1.7 Infection., PMID:34031695
Sars-Cov-2 Infection Screening Using Two Serological Testing Methods., PMID:34009193
The Magnitude and Functionality of SARS-CoV-2 Reactive Cellular and Humoral Immunity in Transplant Population Is Similar to the General Population Despite Immunosuppression., PMID:33988334
Identification of natural SARS-CoV-2 infection in seroprevalence studies among vaccinated populations., PMID:33907763
For research use only. Not for human or drug use.
